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Thromboembolic events in COVID-19 patients can be one of the factors that aggravate the disease and increase 
mortality. When severe hypoxemia and hypotension occur in COVID-19 patients, the possibility of embolism 
should be considered. As a result, anticoagulant therapy in COVID-19 patients has an essential role in lowering 
disease severity and mortality. Many studies report that giving anticoagulants to COVID-19 patients can reduce 
mortality. Therefore, it is important to understand the role and use of anticoagulant therapy in cases of 
COVID-19. Several guidelines that have been issued by several health organizations in the world and Indonesia 
can be used as guidelines for clinicians to start anticoagulant therapy in cases of COVID-19. Various anticoagulant 
drug regimens have also been recommended to be used both as prophylaxis and as therapy for thromboembolism 






 In March 2020, the World Health Organization (WHO) 
formally declared the coronavirus disease 2019 (COVID-19) as a 
pandemic.1 COVID-19 disease is associated with a significant rate of 
thromboembolic events in critically ill patients. The most prevalent 
thrombotic event is venous thromboembolism (VTE), which has been 
documented in up to 23% of COVID-19-treated critically sick patients. 
As a result, there has been a lot of clinical and research interest in 
establishing whether or not this population requires stronger thrombo-
prophylaxis regimens. Critically ill individuals, on the other hand, may 
be more susceptible to bleeding problems, which can also arise in 
Critical illness caused by COVID-19. The best thromboprophylaxis 
method for balancing these thromboses and bleeding risks is 
uncertain.2
 If there are no contraindications to anticoagulation, it is 
suggested that every patient with moderate to severe COVID-19 who is 
hospitalized get preventive anticoagulation (eg active bleeding or 
severe thrombocytopenia). The IMPROVE score (Table 1) can also be 
used to assess bleeding risk. System/organ abnormalities and comor-
bidities should be assessed before anticoagulants are given to 
determine the risk of bleeding and the kind of bleeding. If the patient 
has no absolute or relative contraindications (active bleeding, history of 
heparin allergy or heparin-induced thrombocytopenia, history of 
previous bleeding, platelet count 25,000/mm3, severe hepatic impair-
ment), Low molecular weight heparin should be used as prophylactic 
anticoagulation. In hospitalized moderate/severe COVID-19 patients, a 
normal dose of 1 x 0.4 cc subcutaneously or 5,000 units twice daily 
subcutaneously of molecular-weight heparin (LMWH) or unfractionat-
ed heparin (UFH) can be recommended in critically ill patients, 
intermediate prophylactic doses (enoxaparin 2 x 0.4 cc, low-intensity 
heparin infusion) may be considered.3
 Prophylaxis with standard-dose fondaparinux can also be 
considered in hospitalized COVID-19 patients, but in critically ill 
COVID-19 patients it is not the first choice because, in unstable 
patients, kidney problems often occur.3
 All patients who are admitted with COVID-19 infection 
should be considered for anticoagulation at conventional preventive 
doses, according to the European Society of Cardiology (ESC). 
COVID-19 infection causes respiratory symptoms, as well as chest pain 
and hemoptysis, in many patients. These symptoms are quite similar to 
the signs of acute PE, which could lead to an underdiagnosis of this 
serious condition. Only order diagnostic testing for PE if it is clinically 
suspected; nonetheless, a low suspicion level is recommended. In 
patients with COVID-19, the sensitivity of D-dimer tests may be lower 
than in other clinical scenarios. Even so, using D-dimer thresholds that 
are based on pre-test probability is a great approach to get started with 
pre-test probability and D-dimer laboratory examination. This might 
make the deployment of resources and staff for bringing a patient to the 
radiology department, complete with all requisite isolation procedures, 
more efficient.5 
 Figure 1 shows an approach developed by Atallah et al for 
providing anticoagulation to COVID-19 patients. Anticoagulant 
medication should be administered to individuals at high risk for 
thrombosis, who have dyspnea, a respiratory rate of more than 24 beats 
per minute, oxygen saturation of less than 90%, and elevated levels of 
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CRP, D-dimer, and fibrinogen in the ICU, a parenteral heparin drip 
protocol with a target prothrombolastin time of 60-85 seconds should 
be started under close observation. Non-ICU patients should receive 
subcutaneous enoxaparin 1 mg/kg twice daily, or follow the heparin 
protocol as directed for ICU patients. This recommendation also recom-
mends the use of point-of-care ultrasound in the treatment of deep 
venous thrombosis (DVT). If a positive result is achieved, anticoagulant 
therapy should be continued. In the meantime, if the results are 
negative, it is recommended that the treatment be reduced to subcuta-
neous enoxaparin 40 mg twice a day.6
 Anticoagulants are not recommended in COVID-19 patients 
who are not hospitalized or have finished treatment in a hospital, 
according to the National Institute of Health's Coronavirus Disease 
2019 (COVID-19) Treatment Guidelines, unless the patient is a partici-
pant in a clinical trial. This is due to the low incidence of VTE among 
outpatients, even when preventive anticoagulants are not used routine-
ly. However, if the patient is not at high risk of bleeding, post-hospital 
prophylactic anticoagulation may be considered in patients who are 
discharged early due to excess hospital capacity or who previously had 




Figure 1 Tailored algorithm/protocol for the management of coagulopathy in COVID-19 patients. *High bleeding risk patients are excluded. Also 
exclude patients with platelet count <50 000; INR >2. **FEU, fibrinogen equivalent unit. ***Adjust enoxaparin dose for renal failure. (Source: from 
Attalah et al, 2020).6
 Based on these guidelines, it can be concluded that anticoag-
ulation is recommended in all COVID-19 patients who do not have 
contraindications to anticoagulant therapy. Currently, LMWH is the 
most recommended regimen of choice as anticoagulant therapy in 
COVID-19 patients. The dose of administration is adjusted to the 
clinical condition of each patient and is influenced by the presence of 
conditions that may co-exist in the patient. Until now, prophylactic 
anticoagulation is still the strongest recommendation for COVID-19 
patients.
 Giving anticoagulants to COVID-19 patients cannot be 
separated from the possibility of side effects that can arise due to 
bleeding complications, toxicity, or because of drug interactions that 
can occur between anticoagulant drugs and other drugs that are also 
given to patients. Therefore, close monitoring of the use of anticoagu-
lants is required. In addition, thromboembolic events can still occur 
even with prophylactic anticoagulation, so it is important to ensure that 
the dose given is appropriate and appropriate for the patient's 
condition. The benefits and risks of bleeding and thrombosis should be 
considered before starting anticoagulant therapy in COVID-19 patients.
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Risk factors
Moderate renal failure (CrCl 30 - 50 ml/min.) 
Male Sex 
Age 40 - 84 years
Active Cancer 
Rheumatic disease 
Central venous catheters 
Admissions in Intensive Care 
Severe Renal Failure (CrCl < 30 ml/min.) 
Liver insufficiency (INR > 1.5) 
$JH
Thrombocytopenia (<50 × 109 cell/L) 
Recent (3 months) bleeding 















Table 1. IMPROVE score
1RWH,IWKHVFRUHWKHRYHUDOOUDWHRIPDMRUEOHHGLQJVLVDQG
clinically relevant non-major bleedings is 4.1%; If the score < 7, the 
overall rate of major bleedings is 1.5% and clinically relevant non-major 
bleedings is 0.4%. (Source: Adapted from AlHajri L, Gebran N, 2015).4 
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